Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561956 | 1.00 | EPHX2 (0.63) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL118052 | 1.00 | EPHX2 (0.63) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL7913189 | 0.96 | EPHX2 (0.59) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL8366872 | 0.90 | EPHX2 (0.75) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL5189498 | 0.88 | EPHX2 (0.65) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL22932201 | 0.88 | EPHX2 (0.65) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL15939984 | 0.88 | EPHX2 (0.62) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL30833078 | 0.88 | EPHX2 (0.62) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL29341843 | 0.88 | EPHX2 (0.62) | EPHX2KMT2AFABP7FABP5CASP3 | |
| SCHEMBL8239124 | 0.87 | EPHX2 (0.60) | EPHX2KMT2AFABP7FABP5MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577200-B2 | High-throughput method to rapidly add chemical moieties to a small molecule library | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| EP-4590670-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025133085-A1 | SELECTIVE NPY5R AGONISTS WITH HIGH CHEMICAL AND METABOLIC STABILITY | PEPHEXIA THERAPEUTICS APS (DK) | 2025-06-26 | — | — | WO | disclosed |
| EP-4464341-A2 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München, in Vertretung des Freistaates Bayern (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024233346-A1 | EPHA4 ANTAGONISTS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4008359-B1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | UNIV MUENCHEN TECH (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-114502528-B | Imaging and therapeutic compositions | 墨尔本大学 | 2024-09-06 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20220363623-A1 | IMAGING AND THERAPEUTIC COMPOSITIONS | THE UNIVERSITY OF MELBOURNE (AU) | 2022-11-17 | — | — | US | disclosed |
| US-11497819-B2 | PSMA ligands for imaging and endoradiotherapy | Technische Universität München (DE) | 2022-11-15 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4031520-A1 | IMAGING AND THERAPEUTIC COMPOSITIONS | The University of Melbourne (AU) | 2022-07-27 | — | — | EP | disclosed |
| EP-4008359-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2022-06-08 | — | — | EP | disclosed |
| CN-114502528-A | Imaging and therapeutic compositions | 墨尔本大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-3723815-B1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | UNIV MUENCHEN TECH (DE) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022060459-A1 | HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220089537-A1 | HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2022-03-24 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | EPHX2 4299/4885KMT2A 4690/4885FABP7 2453/4885 |
| US-20220089537-A1 | HIGH-THROUGHPUT METHOD TO RAPIDLY ADD CHEMICAL MOIETIES TO A SMALL MOLECULE LIBRARY | PDE8B, ACP1, BLVRB | EPHX2 913/4885KMT2A 754/4885FABP7 2403/4885 |
| US-20220363623-A1 | IMAGING AND THERAPEUTIC COMPOSITIONS | CA13, CA12, CA1 | EPHX2 750/4885KMT2A 1837/4885FABP7 43/4885 |
| US-12577200-B2 | High-throughput method to rapidly add chemical moieties to a small molecule library | CBR3, CBR1, NR2E3 | EPHX2 416/4885KMT2A 1404/4885FABP7 3316/4885 |
| US-11497819-B2 | PSMA ligands for imaging and endoradiotherapy | KLK3, FOLH1, EEA1 | EPHX2 1147/4885KMT2A 3352/4885FABP7 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.